G1 Therapeutics, Inc.

NASDAQ:GTHX

7.13 (USD) • At close September 6, 2024
Bedrijfsnaam G1 Therapeutics, Inc.
Symbool GTHX
Munteenheid USD
Prijs 7.13
Beurswaarde 376,165,966
Dividendpercentage 0%
52-weken bereik 1.08 - 7.19
Industrie Biotechnology
Sector Healthcare
CEO Mr. John E. Bailey Jr.
Website https://www.g1therapeutics.com

An error occurred while fetching data.

Over G1 Therapeutics, Inc.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive

Vergelijkbare Aandelen

XOMA Corporation logo

XOMA Corporation

XOMA

27.28 USD

Altimmune, Inc. logo

Altimmune, Inc.

ALT

6.2 USD

Kamada Ltd. logo

Kamada Ltd.

KMDA

4.23 USD

Semler Scientific, Inc. logo

Semler Scientific, Inc.

SMLR

23.63 USD

Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc.

NVCT

6.18 USD

Entrada Therapeutics, Inc. logo

Entrada Therapeutics, Inc.

TRDA

14.8 USD

Accuray Incorporated logo

Accuray Incorporated

ARAY

1.92 USD

Alpha Teknova, Inc. logo

Alpha Teknova, Inc.

TKNO

4.59 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)